Drugs / Eriblin
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT06135714 Background | Nov 2023 → Nov 2029 expected | breast cancer | Tokyo Medical and Dental University | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Eriblin | “S-1 or Capecitabine or Eriblin (previously treated with taxane)” NCT06135714 ↗ |